Gotham Asset Management LLC Acquires 108,494 Shares of Pfizer Inc. (NYSE:PFE)

Gotham Asset Management LLC boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 333.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 141,040 shares of the biopharmaceutical company's stock after acquiring an additional 108,494 shares during the quarter. Gotham Asset Management LLC's holdings in Pfizer were worth $3,742,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at about $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer during the fourth quarter worth about $27,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer in the 4th quarter worth about $28,000. Finally, Noble Wealth Management PBC purchased a new stake in Pfizer in the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 3.8%

PFE opened at $22.01 on Thursday. The company has a 50 day moving average of $23.80 and a 200 day moving average of $25.44. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a market cap of $125.13 billion, a PE ratio of 15.61, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.82 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.81%. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PFE. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.